Vertex Pharmaceuticals (VRTX) closed at $542.62 on November 12, 2026, down 0.8% from the previous close, on volume of 894,069 shares (30-day average 1,451,245).
Data as of November 12, 2026.
12-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Nov 2, 2026 | Condor With Puts (Skip Strike) | 18-Dec-26440 : 500 : 510 : 550 P | 3,600 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 11, 2026. See the 10 largest for 30, 60 and 90 days
Vertex Updates JOURNAVX Pain Study as Investors Await Results
TipRanks (Thu, 12-Nov 11:32 AM ET)
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX) and DaVita (DVA)
TipRanks (Thu, 12-Nov 9:50 AM ET)
Vertex Earnings Call Signals Broad-Based Growth Ahead
TipRanks (Sun, 8-Nov 7:15 PM ET)
Vertex to Participate in Upcoming Investor Conferences
Business Wire (Wed, 4-Nov 4:00 PM ET)
Vertex Reports Third Quarter 2026 Financial Results
Business Wire (Mon, 2-Nov 4:01 PM ET)
Business Wire (Fri, 23-Oct 1:42 PM ET)
Vertex Appoints Daniel Brennan to its Board of Directors
Business Wire (Tue, 20-Oct 4:05 PM ET)
Vertex to Present New Data on ALYFTREK at the North American Cystic Fibrosis Conference
Business Wire (Fri, 9-Oct 1:15 PM ET)
Vertex to Announce Third Quarter 2026 Financial Results November 2nd
Business Wire (Wed, 7-Oct 4:00 PM ET)
Market Chameleon (Tue, 22-Sep 5:48 AM ET)
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex is focused on diversifying its portfolio through Casgevy (gene-editing therapy for beta thalassemia and sickle-cell disease), Journavx (non-opioid pain drug for moderate-to-severe acute pain), and Palsonify (for acromegaly). Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases, cell therapies to deliver a functional cure for type 1 diabetes, povetacicept (for IgA nephropathy).
Vertex Pharmaceuticals trades on the NASDAQ stock market under the symbol VRTX.
As of November 12, 2026, VRTX stock price declined to $542.62 with 894,069 million shares trading.
VRTX has a beta of 0.41, meaning it tends to be less sensitive to market movements. VRTX has a correlation of 0.03 to the broad based SPY ETF.
VRTX has a market cap of $137.53 billion. This is considered a Large Cap stock.
Last quarter Vertex Pharmaceuticals reported $3 billion in Revenue and $4.76 earnings per share. This beat revenue expectation by $13 million and exceeded earnings estimates by $.06.
In the last 3 years, VRTX traded as high as $568.67 and as low as $341.90.
The top ETF exchange traded funds that VRTX belongs to (by Net Assets): VTI, VOO, QQQ, IVV, SPY.
VRTX has outperformed the market in the last year with a price return of +26.4% while the SPY ETF gained +12.0%. VRTX has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +2.4% and +2.4%, respectively, while the SPY returned -1.5% and -2.0%, respectively.
VRTX support price is $535.63 and resistance is $558.43 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that VRTX shares will trade within this expected range on the day.
